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Dioxygenases of the TET family impact genome
functions by converting 5-methylcytosine (5mC) in
DNA to 5-hydroxymethylcytosine (5hmC). Here, we
identified TET2 as a crucial regulator of mast cell dif-
ferentiation and proliferation. In the absence of TET2,
mast cells showed disrupted gene expression and
altered genome-wide 5hmC deposition, especially
at enhancers and in the proximity of downregulated
genes. Impaired differentiation of Tet2-ablated cells
could be relieved or further exacerbated by modu-
lating the activity of other TET family members, and
mechanistically it could be linked to the dysregulated
expression of C/EBP family transcription factors.
Conversely, the marked increase in proliferation
induced by the loss of TET2 could be rescued exclu-
sively by re-expression of wild-type or catalytically
inactive TET2. Our data indicate that, in the absence
of TET2, mast cell differentiation is under the control
of compensatory mechanisms mediated by other
TET family members, while proliferation is strictly
dependent on TET2 expression.
INTRODUCTION
DNA methylation at promoters is traditionally considered a
stable modification linked to gene silencing and with pivotal
regulatory roles in mammalian development. The Ten-Eleven-
Translocation (TET) 1–3 proteins are a-ketoglutarate and Fe2+-
dependent enzymes able to epigenetically alter DNA by oxidizing
5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and
further oxidation products (Ito et al., 2011; Tahiliani et al., 2009).
Oxidized cytosines serve as intermediates in the process of DNA
demethylation, enabling the dynamic turnover of this modifica-
tion. Moreover, due to the existence of 5mC- and 5hmC-selec-
tive or preferential binders, including a broad panel of adapters1566 Cell Reports 15, 1566–1579, May 17, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://and chromatin regulators (Pastor et al., 2013), TET activity also
directly controls the recruitment of proteins or complexes to
methylated DNA.
Different TET family members can have unique and non-over-
lapping functions, as highlighted by the phenotypes displayed by
TET-deficient animals. While the phenotype of mice lacking
TET1 is quite mild, mice lacking TET2 display late-onset hemato-
logical abnormalities and lack of TET3 is embryonic lethal (re-
viewed in Pastor et al., 2013). In hematopoietic stem cells
(HSCs), lack of TET2 leads to decreased global genomic levels
of 5hmC, increased size of the progenitor pool, and enhanced
multi-lineage repopulating ability, with a developmental skewing
toward the monocyte/macrophage lineage (An et al., 2015; Ko
et al., 2011, 2015). A division of labor between the different
TET family members in controlling 5hmC distribution is sug-
gested by the observation that, in mouse embryonic stem cells
(mESCs), TET1 is primarily responsible for 5hmC modifications
at the level of promoter regions and transcriptional start sites
(TSSs), whereas TET2 mostly regulates levels of 5hmC at en-
hancers and in gene bodies (Hon et al., 2014; Huang et al.,
2014; Williams et al., 2011). In addition, TET proteins can play
unique roles partly due to their specific interactions with co-reg-
ulators, allowing them to modulate gene expression indepen-
dently of DNA hydroxymethylation. For example, TET2 and
TET3 interact with the enzyme O-linked b-N-acetylglucosamine
(O-GlcNAc) transferase (OGT) to facilitate its activity (Chen
et al., 2013; Deplus et al., 2013), and TET2 was shown to interact
with HDAC2, thusmodulating transcription of the Il6 gene (Zhang
et al., 2015). TET2 also can also contribute to gene silencing by
facilitating the recruitment of the Polycomb Repressive Complex
2 to CpG dinucleotide-rich gene promoters (Wu et al., 2011).
Conversely, TET1 (but not TET2) can be incorporated into the
SIN3A co-repressor complex, resulting in transcriptional effects
independent of 5hmC (Williams et al., 2011).
As an important link of these protein activities to disease, TET2
frequently acquires loss-of-function mutations in different types
of cancers, notably myeloid neoplasms (Ko et al., 2010), while
TET1 and TET3 are rarely mutated in hematological malig-
nancies (Abdel-Wahab et al., 2009; Huang and Rao, 2014). In)
creativecommons.org/licenses/by-nc-nd/4.0/).
humans, TET2 also was shown to be involved in neoplastic dis-
eases of mast cells, a cell type belonging to the innate myeloid
lineage. Mast cellactivation is involved in the response to a vari-
ety of pathogens and allergens, making these cells an important
effector type not only in innate immunity but also in allergic reac-
tions and asthma. In addition, alterations in the number, localiza-
tion, and reactivity of mast cells are typical features of systemic
mastocytosis (SM), a myeloproliferative disorder characterized
by an increase in mast cell burden (Theoharides et al., 2015).
Multiple genetic and epigenetic mechanisms can contribute to
the onset and severity of all types of mast cell-related diseases;
in SM, overall reduced levels of 5hmC correlated with the burden
of themutated D816V KIT oncogene (Leoni et al., 2015), and loss
of TET2 cooperated with the KIT D816V mutation to transform
mast cells to a more aggressive phenotype (De Vita et al.,
2014; Soucie et al., 2012). Although mast cells are central in
allergic and anaphylactic reactions and represent the patho-
genic cell type in SM, themechanisms underlying the complexity
of mast cell phenotypes upon alteration of levels of genomic
5hmC are unknown.
Here we investigated the role of TET2 in regulating differen-
tiation and functions of mast cells. We found that the lack of
TET2 led to a complex phenotype characterized by cell-intrinsic
delay in differentiation, defects in cytokine production, as well
as pronounced hyperproliferation. These alterations were
accompanied by extensive transcriptome changes and altered
genome-wide 5hmC distribution, especially at the level of en-
hancers and in the proximity of (and within) genes that resulted
to be downregulated in the absence of Tet2. Tet2 ablation also
led to dysregulated expression of several transcription factors
(TFs), two of which (C/EBPa and C/EBPε) were validated as
contributing to the differentiation defects. Importantly, while
the defects in cell differentiation could be further exacerbated
or diminished by modulating the activity of other TET family
members, the increased proliferation could be normalized
only by the re-expression of TET2 regardless of its enzymatic
activity. These findings indicate not only compensatory roles
of the different TET family members on specific pathways,
but also the existence of phenotypes that are strictly TET2
dependent. Overall, our data dissect the role of TET2-mediated
regulation of mast cell differentiation and function, uncover
transcriptional pathways that are predominantly dysregulated
as a consequence of TET2 loss, and identify both enzymatic
activity-dependent and -independent functions of TET2 in
mast cells.
RESULTS
Altered Differentiation, Proliferation, and Cytokine
Expression in the Absence of TET2
To investigate the role of TET2 in mast cell biology, we first as-
sessed the effects of Tet2 gene deletion on cell differentiation
and function. We differentiated mast cells by culturing bone
marrow progenitors of Tet2-deleted animals (Ko et al., 2011)
and wild-type (WT) littermates with IL-3. Cell differentiation was
monitored by surface staining of relevant mast cell and myeloid
markers (Figure 1A). In these culture conditions, more than 90%
of WT (Tet2+/+) cells differentiated to mast cells (Kit+ FcεRIa+) bythe end of the third week of culture (Figures 1A–1C) (Deho’ et al.,
2014; Mayoral et al., 2011; Mayoral and Monticelli, 2010; Rusca
et al., 2012); however, Tet2/ cultures showed reduced per-
centages ofmast cells, aswell as aberrant expression ofmarkers
for other myeloid cells (Mac1 and Ly6G) (Figure 1A), suggesting
delayed or altered differentiation. Cultures from heterozygous lit-
termates showed an intermediate phenotype, pointing toward a
gene-dosage effect of Tet2 expression. Visual inspection of cell
morphology was consistent with a differentiation defect (Fig-
ure S1A). Complete mast cell differentiation could not be
achieved even after 6 weeks of culture (Figure 1B). While after
3 weeks Tet2+/+ cultures consisted of R90% mast cells, only
50% of the cells in Tet2/ cultures had reached terminal dif-
ferentiation (Figure 1C). However, once differentiated, Tet2/
cells expressed similar levels of Kit and FcεRIa as Tet+/+ cells
and stably maintained their phenotype over time (Figure S1B).
Differentiation performed in the presence of both IL-3 and SCF
(another mast cell differentiation and survival factor) did not
rescue the differentiation defect associated with Tet2 deficiency
(Figure S1C).
In HSCs, lack of Tet2was shown to lead to a cell-autonomous
increase in the size of the progenitor pool, delayed differentia-
tion, and skewed development toward the monocyte/macro-
phage lineage, at least in vitro (Ko et al., 2011). To assess
whether the observed defects were due to a cell-intrinsic de-
layed differentiation to mast cells or to increased differentiation
to other myeloid lineages, we evaluated the phenotypic stability
of the various subpopulations present in Tet2/ cultures.
Tet2+/+ and Tet2/ cells were differentiated for 10 days and
then sorted into Kit–/lo FcεRIa– progenitors, Kit– FcεRIa+ interme-
diates, representing a well-defined granulocyte-monocyte pro-
genitor (GMP) stage (Qi et al., 2013), and Kit+ FcεRIa+ mast cells;
we then followed their fate for up to 24 days. We found that
Tet2/ cells maintained the ability to differentiate from precur-
sors to mast cells through the intermediate GMP stage (Figures
S1D and S1E), indicating delayed differentiation in the absence
of TET2. We therefore assessed proliferation and effector
functions of differentiated mast cells, which were separated as
Kit+ FcεRIa+ in all experiments. First, we evaluated cell survival
in response to withdrawal of IL-3, which was unaffected by
Tet2 deletion (Figure S2A). Conversely, by assessing BrdU incor-
poration in response to IL-3 treatment (Figure S2B) (Deho’ et al.,
2014), we found that Tet2/ mast cells showed significant
hyperproliferation compared to their Tet2+/+ counterparts, while
Tet2+/ cells displayed an intermediate phenotype, pointing
again toward a gene-dosage effect of Tet2 in regulating mast
cellproliferation (Figures 1D and 1E).
We next assessed cytokine expression. Cells were stimulated
with IgE and antigen, followed by intracellular staining for three
cytokines that are abundantly produced by activated mast cells,
namely IL-6, TNF-a, and IL-13. We observed no difference in
basal cytokine expression between Tet2/ and Tet2+/+ cells
(Figures S2C–S2E). Upon stimulation, the percentage of cells ex-
pressing these cytokines was reduced in Tet2/ mast cells
compared to their WT counterparts, as assessed by intracellular
staining (Figures 1F and 1G; Figures S2C and S2D), although the
overall amount of secreted cytokines was more comparable, at
least after 12 hr of stimulation (Figure S2E). Interestingly, theCell Reports 15, 1566–1579, May 17, 2016 1567
Figure 1. Altered Mast Cell Differentiation, Proliferation, and Effector Functions in the Absence of Tet2
(A) Bonemarrow cells from Tet2+/+, Tet2/, and Tet2+/micewere differentiated tomast cells. Shown is one representative surface staining formast cell markers
(Kit and FcεRIa) and other myeloid markers (Mac1 and Ly6G) after 3 weeks of differentiation.
(B) Percentage of Kit+ FcεRIa+ mast cells in bone marrow cultures of Tet2+/+ and Tet2/ littermates, over 6 weeks of differentiation, is shown (n = 4; two-way
ANOVA, ***p < 0.0003 and **p = 0.0084).
(C) Same as (B), except that quantification for seven independent experiments at the third week of differentiation is shown. Each dot represents one biological
sample (unpaired t test, two-tailed; mean ± SEM).
(D) Mast cell proliferation was assessed by BrdU incorporation assay. Kit+ FcεRIa+ mast cells were either physically separated at least 1 day before the
experiment or were gated at the analysis step.
(E) Same as (D), except that the compiled result of 13 independent experiments is shown (paired t test, two tailed; mean ± SEM).
(F) Cells were stimulated with IgE and antigen before intracellular cytokine staining. One representative staining for TNF-a expression is shown.
(G) Same as (F), except that the compiled results for six (IL-6 and TNF-a) or seven (IL-13) independent experiments are shown (paired t test, two tailed;
mean ± SEM).
See also Figures S1 and S2.ability of Tet2/ mast cells to release the pre-stored content of
cytoplasmic granules was comparable to that of their WT coun-
terparts (Figure S2F), suggesting that some effector functions of
differentiated cells were unaffected by Tet2 deficiency. Overall,
these data point toward a key role of TET2 in regulating predom-
inantly mast cell differentiation and proliferation.
Transcriptional Impact of Tet2 Deletion in Mast Cells
To investigate the altered gene expression programs underlying
the phenotypic defects of Tet2/mast cells, we performed RNA1568 Cell Reports 15, 1566–1579, May 17, 2016sequencing (RNA-seq) to compare the transcriptome of these
cells with that of WT mast cells. To compare populations that
were as homogenous as possible, we sorted Tet2/ mast cells
(Kit+ FcεRIa+) to R95% purity. We profiled two independent
biological replicates using >80 million mapped paired-end reads
per sample. Differentially expressed genes (DEGs) were identi-
fied using Cuffdiff (Trapnell et al., 2013) with standard parame-
ters (fold changeR 2, p% 0.05, and fragments per kilobase of
exon per million fragments mapped [FPKM] > 1 in at least one
of the two conditions). Pairwise analysis of the transcriptomes
Figure 2. RNA-Seq Analysis Identifies Dysregulated Genes and Functional Pathways in Tet2/ Mast Cells
(A) Total RNA from Tet2+/+ and Tet2/ mast cells was used for RNA-seq. DEGs are shown in a hierarchically clustered heatmap. For hierarchical clustering,
distance metric between rows was calculated according to the Pearson correlation on the log2 of FPKM values and then normalized by Z score. Lowest Z score
values are dark blue and highest values are bright red.
(B and C) Enriched GO functional categories (left) and over-represented TF consensus DNA-binding sites (right) in up- (C) and downregulated (B) genes were
identified using REVIGO and PSCAN, respectively. GO terms are visualized in semantic similarity-based scatterplots. Bubble color indicates the p value as
follows: blue and green bubbles are GO terms with more significant p values compared to orange and red bubbles. Bubble size shows howmuch the GO term is
represented in theGOdatabase. Selected representative categories are shown. For PSCAN analyses, each over-represented TF subfamily is shown according to
the obtained Welch p values (log10).
See also Figure S3.of WT and Tet2/ mast cells identified 1,149 DEGs that were
either downregulated (n = 535) or upregulated (n = 614) in
Tet2/ cells (Figure 2A), pointing toward complex (and likely
both direct and indirect) effects of TET2 on the mast cell tran-
scriptome (Lu et al., 2014). A gene ontology (GO) analysis of
the DEGs is shown in Figures 2B and 2C. GO categories with
highly significant p values for the downregulated genes included
inflammatory and defense responses, as well as cytokine pro-
duction and cell differentiation, all consistent with the observed
dysregulated mast cell functions (Figure 2B). In keeping with
the hyperproliferative phenotype of Tet2/ mast cells, the top-
ranking GO categories for the upregulated genes included cell
division-related terms, such as cell cycle and proliferation,
DNA replication and metabolic processes, and DNA damage
and repair responses (Figure 2C).
To identify possible TFs that could be common regulators of
the genes affected by Tet2 deletion, we analyzed the regions
surrounding the TSSs (from 500 bp to +250 bp) of the identi-
fied DEGs utilizing PSCAN, a computational tool that investi-gates over- or under-represented TF consensus DNA-binding
motifs (position weigh matrixes [PWMs], Zambelli et al.,
2009). Consistent with the observed phenotype and the en-
riched GO categories, PSCAN analysis of PWMs at upregulated
genes revealed an enrichment in consensus DNA-binding mo-
tifs recognized by TF families controlling cell cycle and prolifer-
ation, such as E2Fs and Myc/Max (Figure 2C) (Amati et al.,
2001; Gallant and Steiger, 2009; Ren et al., 2002). The p values
of the PWMs retrieved by the same analysis at downregulated
genes (including MAZ-like TFs, MEIS, and others) were less
significant, which may be in line with the possibility that, rather
than affecting the function of specific TFs, TET2 loss impacts a
broad and heterogeneous set of genomic regions and regulato-
ry elements.
We validated our RNA-seq data using at least four indepen-
dent samples of Tet2+/+ and Tet2/ mast cells by analyzing the
mRNA levels of selected DEGs, such as the genes encoding for
the myeloperoxidase Mpo, the TF C/EBPa, the mast cell prote-
ase 8 (Mcpt8), the serine protease Prss34, the adhesionCell Reports 15, 1566–1579, May 17, 2016 1569
Figure 3. VitC Treatment Restores Gene Expression in Tet2/ Mast Cells
(A) FPKM values are plotted for selected DEGs identified by RNA-seq (mean ± SEM).
(B) The same genes as in (A) were validated by qRT-PCR. Each dot represents one independent biological sample (n = at least 4). Shown is the expression relative
to the endogenous control Tbp and to one Tet2+/+ sample.
(C) After 2.5 weeks of differentiation, Tet2+/+ and Tet2/ mast cells were either left untreated or were supplemented with 10 and 50 mg/ml VitC for 10 days. The
DNA was extracted and 2-fold dilutions starting from 500 ng were spotted on a membrane. The 5hmC content was assessed using an anti-5hmC antibody.
(D) Cells were treated as in (C) with medium supplemented with 50 mg/ml VitC for 10 days. Total RNA was then extracted and gene expression analyzed by
qRT-PCR. Shown is the expression relative to Tbp. Expression of all genes also is related to one Tet2+/+ sample except forMpo that was mostly undetectable in
Tet2+/+ cells (n = at least 3, mean ± SEM).
See also Figure S4.molecule Amica1, and the tyrosine phosphatase Ptpn13
(Figures 3A and 3B). We also assessed microRNA (miRNA)
expression globally by array profiling. We did not detect any
significant and reproducible change in miRNA expression (Fig-
ure S3), suggesting that miRNA expression in mast cells is not
significantly influenced by the lack of TET2 and is therefore un-
likely to explain the phenotypes observed in the absence of this
enzyme.
TET3 Can Only Partially Compensate for the Lack of
TET2 in Mast Cells
To investigate whether the alterations in gene expression that
were observed in the absence of TET2 could be rescued by
the enzymatic activity of other TET family members (namely
TET1 and TET3), we took advantage of the fact that vitamin C
(VitC) enhances the catalytic activity of TET proteins by acting
as a co-factor that maintains the essential atom of iron in the
catalytic site in a reduced state (Fe2+) (Blaschke et al., 2013;
Yin et al., 2013). Differentiated mast cells were treated with
VitC prior to analysis of overall levels of genomic 5hmC by
dot blot (Figure 3C). Tet2/ mast cells had reduced levels of
5hmC compared to their WT counterparts (compare lanes
1 and 4); medium supplementation with VitC, however, strongly
increased the global 5hmC levels in both Tet2+/+ and Tet2/
mast cells (Figure 3C). In the absence of TET2, such effect
was most likely due to the enhanced enzymatic activity of other1570 Cell Reports 15, 1566–1579, May 17, 2016TET family members (Yue et al., 2016), since VitC treatment did
not significantly increase the expression of any Tet mRNA
(Figure S4).
We next assessed whether enhanced 5hmC deposition driven
by VitC supplementation could rescue the differential expression
of TET2-regulated genes. VitC treatment induced a partial
normalization of gene expression, since genes overexpressed
in Tet2/ cells (Mpo, Mcpt8, and Prss34) returned to near-
normal levels. The expression of some downregulated genes
(Amica1 and Ptpn13) was induced, albeit modestly (Figure 3D).
Our data indicate that altered gene expression in the absence
of Tet2 is mainly due to reduced 5hmC production, and this
can be rescued, at least in part, by enhancing the activity of other
TET family members.
Since we observed that enhanced 5hmC deposition could
partially rescue gene expression changes due to the absence
of Tet2, we assessed whether it also could rescue mast cell pro-
liferation, effector functions, and differentiation. First, we as-
sessed cell proliferation in Tet2/ mast cells treated with or
without VitC. Strikingly, the difference in proliferation between
Tet2/ and Tet2+/+ cells remained unaffected by VitC treatment
(Figures 4A and 4B), suggesting that the hyperproliferation
induced by the absence of Tet2 was strictly TET2 dependent
and independent of the enzymatic activity of other TET proteins.
Conversely, VitC treatment was sufficient to fully restore the abil-
ity of cells to express IL-6, TNF-a, and IL-13 at levels that were
Figure 4. VitC Treatment Restores Mast Cell Differentiation and Cytokine Production, but Does Not Normalize Proliferation
(A) Tet2+/+ and Tet2/mast cells were treated with 50 mg/ml VitC for 10 days, after which proliferation was assessed by BrdU incorporation. One representative
experiment is shown.
(B) Same as (A), except that the results of seven experiments are shown (paired t test, two tailed; mean ± SEM).
(C) Tet2/ mast cells were treated as in (A) prior to intracellular cytokine staining. One representative experiment for TNF-a is shown.
(D) Same as (C), except that the results of five (IL-6 and TNF-a) or three (IL-13) experiments are shown.
(E) Tet2+/+ and Tet2/ bone marrow cells were differentiated to mast cells for 2 weeks, after which culture medium was further supplemented with 50 mg/ml VitC
for 8 days. The percentage of mast cells in culture was assessed by surface staining for Kit and FcεRIa. One representative experiment is shown.
(F) Same as (E), except that the results of four experiments are shown. Statistical analysis was performed with two-way ANOVA.comparable to those of WT cells (Figures 4C and 4D). VitC
treatment was similarly able to fully complement the absence
of TET2 by completely rescuing mast cell differentiation (Figures
4E and 4F).
To further investigate whether modulation of the expression of
other TET proteins could influence mast cell functions, we
depleted TET3 in Tet2/ mast cells using small hairpin RNAs
(shRNAs). To test the efficacy of the shRNA sequences, we first
transduced a neuronal cell line (Cashman et al., 1992), as neu-
rons express high levels of TET3 (Hahn et al., 2013), and we as-
sessed global 5hmC levels 7 days after transduction (Figure 5A).
We observed an30% reduction in levels of Tet3mRNA in these
cells, which corresponded to a detectable reduction (up to24%) in the global level of 5hmC (Figure 5A). We therefore
used lentiviral transduction of TET3-specific shRNAs in differen-
tiated Tet2/ mast cells, achieving up to a 43% reduction in
Tet3 expression (Figure 5B). Concordant with the fact that VitC
could not rescue mast cell hyperproliferation in the absence of
Tet2, reduction of TET3 expression had no effect on mast cell-
proliferation in Tet2/ cells (Figures 5C and 5D). Conversely,
depletion of TET3 in Tet2/ bone marrow precursors exacer-
bated the phenotype observed in the absence of Tet2 and led
to a further delay in mast cell differentiation (Figures 5E
and 5F). Our data indicate that, while cytokine production and
mast cell differentiation could be fully restored by mechanisms
that modulate expression or activity of other TET proteins,Cell Reports 15, 1566–1579, May 17, 2016 1571
Figure 5. Knockdown of TET3 Further Exacerbates the Differentiation Defect of Tet2/ Cells, but Does Not Affect Proliferation
(A) NSC-34 cells were transduced with lentiviruses expressing either an irrelevant control hairpin (shLuc) or two different shRNAs against murine TET3 (sh1 and
sh2), alone or in combination. Levels of genomic 5hmC were measured by dot blot. The 2-fold dilution of DNA, starting from 100 ng, was spotted on the
membrane. Values of relative quantification are indicated on the blot.
(B) Tet2/ bone marrow cells were transduced with a mixture of shRNAs against TET3 as in (A) and the expression of Tet3mRNA was measured by qRT-PCR.
Shown is the result of two independent experiments each performed with two biological replicates. Data were normalized to the expression of b2 microglobulin
(unpaired t test, two tailed; mean ± SEM).
(C) Same as (B), except that proliferation of Tet2/ cells transduced with a control hairpin or shTet3 was measured by BrdU incorporation assay. One repre-
sentative result is shown.
(D) Same as (C), except that the results of five experiments are shown (paired t test, two tailed; mean ± SEM).
(E) Tet2/ bonemarrow precursors were transduced as in (B), and cell differentiation was followed over time by surface staining for Kit and FcεRIa. Shown is one
representative result after 2.5 weeks of differentiation.
(F) Same as (E), except that the data of two different experiments are shown, each performed with two independent biological replicates. Statistical analysis was
performed with two-way ANOVA.control of mast cell proliferation appeared to be predominantly
TET2 dependent.
Altered Expression of C/EBP TFs Is Sufficient to Impair
Mast Cell Differentiation
Since one of themajor phenotypes observed in Tet2/ cells was
a delay in their differentiation, which could most likely also
contribute to their reduced cytokine production (Tsai et al.,
1991), we investigated whether dysregulated expression of TFs
involved in myeloid differentiation could explain such a pheno-
type. We found that Cebpa and Cebpe were both upregulated
in Tet2/ cells (Figures 3A and 6A, left panel). Because
C/EBPε is involved in regulating multiple steps of myeloid differ-
entiation, especially toward granulocytic lineages (Paul et al.,
2015; Yamanaka et al., 1997), and C/EBPa was shown to influ-
ence the choice in the differentiation toward mast cells or gran-
ulocytes (Iwasaki et al., 2006; Qi et al., 2013), we investigated1572 Cell Reports 15, 1566–1579, May 17, 2016whether dysregulated expression of these TFs could contribute
to the differentiation delay observed in the absence of Tet2.
We transduced hematopoietic precursors with vectors to ex-
press either C/EBPε (Figures 6A–6D) or C/EBPa (Figures 6E
and 6F). Expression of C/EBP TFs in Tet2+/+ cells led to reduced
and delayed mast cell differentiation (Figures 6B and 6F), resem-
bling the phenotype observed in the absence of Tet2, which
could therefore be explained, at least in part, by the dysregulated
expression of C/EBP family members. Accordingly, forced
expression of Cebpe in Tet2/ mast cells (thereby further
increasing its already high expression) led to an even greater
inability of the cells to differentiate (Figure 6D). In agreement
with the effect of C/EBP TFs on differentiation, we also found
that overexpression of C/EBPε induced expression of at least
some of the genes that were found to be induced in the absence
of Tet2, namely Mcpt8 and Prss34 (Figure 6C). Our data show
that increased expression of either Cebpa or Cebpe is sufficient
Figure 6. Dysregulated Expression of C/EBP TFs Leads to Delayed Mast Cell Differentiation
(A) (Left) Expression ofCebpewas assessed in Tet2+/+ and Tet2/mast cells by qRT-PCR (n = 5, each dot represents one biological sample; unpaired t test, two
tailed; mean ±SEM). (Right) Tet2+/+ Lin– bonemarrow hematopoietic precursors were transducedwith a lentiviral vector to express C/EBPε. Expression ofCebpe
was assessed by qRT-PCR. Endogenous control: Tbp.
(B) Tet2+/+ Lin– hematopoietic precursors were transduced as in (A), and mast cell differentiation was assessed over time by surface staining for Kit and FcεRIa.
One representative staining after 2 weeks of differentiation is shown on the left, while the graph on the right shows the results of four independent transductions
(two-way ANOVA, ****p < 0.0001 and ***p = 0.0001).
(C) Same as (B), except that the expression of selected mast cell proteases was measured by qRT-PCR (n = 4, mean ± SEM).
(D) Same as (A) and (B), except that forced expression of C/EBP was performed on bone marrow cells of Tet2/mice. One representative staining at 2 weeks of
differentiation is shown on the left; the graph on the right shows the results of six transductions (two-way ANOVA, pvalues are, from left to right, ***p = 0.0005,
****p < 0.0001, and ***p = 0.0002).
(E) Tet2+/+ Lin– hematopoietic precursors were transduced to express C/EBPa or a control vector. Expression of Cebpa was assessed by qRT-PCR.
(F) Same as (E), with mast cell differentiation assessed by surface staining for Kit and FcεRIa. One representative staining after 1.5 weeks of differentiation is
shown on the left; the graph in the middle shows one representative experiment over time, while the bar graph on the right shows the results of three different
experiments after 1.5 weeks (paired t test, two tailed; mean ± SEM).to determine defective mast cell differentiation, resembling the
phenotype observed in Tet2/ cells.
Altered Genome-wide 5hmC Deposition in the Absence
of Tet2
To gain further insights on the molecular mechanisms that regu-
late mast cell functions in the absence of TET2, we investigated
changes in genome-wide 5hmC deposition by glucosylation, pe-riodate oxidation, and biotinylation (GLIB)-based enrichment of
5hmC and sequencing (GLIB-seq). First, Tet2/ cells showed
an overall enrichment of regions depleted of 5hmC compared
to regions where this modification was increased (Figure 7A;
Figure S5). Specifically, 2,715 peaks were hypo-hydroxymethy-
lated in Tet2/ cells, of which 2,588 classified as distal and 127
as proximal relative to the TSSs of annotated genes. In compar-
ison, only 468 peaks resulted in hyper-hydroxymethylated (437Cell Reports 15, 1566–1579, May 17, 2016 1573
Figure 7. TET2 Reconstitution Reduces Mast Cell Proliferation, Independently of 5hmC Modification
(A) Differentially hydroxymethylated distal regions in Tet2/ mast cells. Hyper-hydroxymethylated peaks are depicted in red, hypo-hydroxymethylated in blue,
and unchanged peaks in gray.
(B) Genomic location of the differentially hydroxymethylated regions is shown.
(C) Functional enrichment analysis of differentially hydroxymethylated regions was performed using GREAT. Selected categories are shown; see Table S8 for the
full list of significant categories.
(D) Distance of hyper- and hypo-hydroxymethylated regions from the nearest dysregulated (up- or downregulated) gene is shown.
(E) Distance of H3K4me1 peaks, as assessed by ChIP-seq of Tet2+/+ cells, from the summit of hypo-hydroxymethylated regions is shown.
(F) Tet2/mast cells were transducedwith an empty vector or with vectors expressingWT or catalytically inactive TET2 (HxD). Levels of 5hmCweremeasured by
dot blot. One representative experiment is shown.
(G) Proliferation of mast cells transduced as in (F) was assessed by BrdU incorporation assay. Each dot represents one independent experiment (paired t test, two
tailed; mean ± SEM).
See also Figure S5.distal and 31 proximal). Finally, 9,725 peaks (9,022 distal and 703
proximal) were common and did not change, while 11,011 peaks
could not be consistently classified. An analysis of the relative
distribution of the genomic location of the hypo- and hyper-hy-
droxymethylated peaks revealed that the vast majority of differ-
entially hydroxymethylated peaks was localized in introns and
intergenic regions (Figure 7B).
Interestingly, a GREAT analysis (McLean et al., 2010) of the
differentially hydroxymethylated regions identified categories
relevant to leukocyte differentiation and proliferation, malignant1574 Cell Reports 15, 1566–1579, May 17, 2016transformation, and mast cell-related processes such as KIT
and histamine signaling (Figure 7C). To better understand the
correlation between altered hydroxymethylation and altered
gene expression in Tet2/ cells, we evaluated the distance
of the hypo- and hyper-hydroxymethylated regions from
genes that were up- or downregulated based on RNA-seq
data. While the hyper-hydroxymethylated peaks did not show
any significant difference in their distance from either up- or
downregulated genes, the hypo-hydroxymethyated peaks
were significantly closer to genes that were downregulated in
Tet2/ cells (Figure 7D), suggesting that, at least for a subset of
genes, levels of TET2-dependent 5hmC may be important to
maintain proper levels of expression.
To better characterize the functional relevance of such hypo-
hydroxymethylated regions in gene expression, we assessed
the genome-wide distribution of H3K4me1 (monomethylated
lysine 4 on the histone H3 N-terminal tail) by chromatin immuno-
precipitation and sequencing (ChIP-seq), since this is a modifi-
cation known to mark enhancers (Heintzman et al., 2007,
2009). We evaluated the distance of H3K4me1 peaks from the
summit of hypo-hydroxymethylated peaks (Figure 7E), and we
found that hypo-hydroxymethylated regions in Tet2/ cells
tended to overlap with H3K4me1-marked regions, a result
consistent with data obtained in other cell types (Hon et al.,
2014; Rasmussen et al., 2015). These data indicate that many
genomic regions are affected by the lack of Tet2 in mast cells
and that hypo-hydroxymethylated regions are significantly
closer to downregulated genes and often associated with tran-
scriptional enhancers, suggesting a direct role for TET2-derived
5hmC in modulating proper expression of these genes, poten-
tially through the maintenance of a demethylated state at the
level of enhancers (Rasmussen et al., 2015).
TET2 Reconstitution, Independent of Its Enzymatic
Activity, Normalizes Mast Cell Proliferation
As shown above, proliferation of Tet2/ mast cells was not
significantly influenced bymodulating levels of 5hmC. Therefore,
to gain further insights on the molecular mechanisms that could
lead to dysregulated proliferation in Tet2/ mast cells, we as-
sessed the role of TET2 enzymatic activity in regulating mast
cell proliferation. We reconstituted Tet2/ mast cells with lenti-
viral vectors expressing the TET2 carboxy-terminal catalytic
domain (amino acids 990–1,912 of mouse TET2), with or without
substitutions in theH3Dmotif (H1302Y andD1304A) that ablate
its enzymatic activity (Ko et al., 2010). As expected, transfection
of HEK293 cells with the WT, but not the mutated plasmid,
showed increased levels of 5hmC in the nucleus, as assessed
by immunofluorescence (Figure S6A). Despite higher levels of
expression of the mutated TET2 H 3 D compared to TET2 WT
(Figure S6B), only TET2 WT was able to increase the levels of
overall genomic 5hmC in Tet2/mast cells (Figure 7F). Analysis
of the expression of genes that were dysregulated in the absence
of TET2 showed partial recovery upon reconstitution, mostly
mediated by TET2 WT (Figure S6C). We subsequently assessed
mast cell proliferation by BrdU incorporation. Surprisingly, both
WT and H 3 D TET2 were able to reduce mast cell proliferation
to a comparable degree that was significantly lower than that ob-
tained with the control vector (Figure 7G). These data suggest
that mast cell proliferation is primarily regulated by an enzymatic
activity-independent function of TET2, consistent also with the
fact that we could not influence cell proliferation by either VitC
treatment or TET3 knockdown (Figures 4A, 4B, 5C, and 5D).
These data indicate that TET2 expression, but not its enzymatic
activity, is required to restrain mast cell proliferation, most likely
through the interaction with other partner proteins.
In summary, our data revealed a complex phenotype induced
by the lack of Tet2 in mast cells, comprising primarily delayed
differentiation and significant hyperproliferation. While the differ-entiation defect could be rescued by mechanisms other than
TET2 expression (for example by the enhanced activity of TET1
and TET3) and it was linked to dysregulated expression of
C/EBP TFs, the increased proliferation appeared to be pre-
dominantly dependent on TET2 and uncoupled from changes
in overall 5hmC deposition in mast cells.
DISCUSSION
Our study establishes an important role for TET2 in regulating
mast cell differentiation, proliferation, and functions, which
may impact all mast cell-related diseases. The absence of
Tet2 led to a widespread alteration of 5hmC distribution and
gene expression; specifically, we found that many genomic re-
gions (especially enhancers) showed reduced levels of 5hmC,
and they were associated with functional categories related to
myeloid cell homeostasis and mast cell activities. Among the
genes with altered expression, we found that increased levels
of C/EBP TFs could, at least in part, contribute to the delayed
differentiation observed in Tet2/ cells. Interestingly, there
was no specific single TF that stood out as a potential candidate
to modulate cell proliferation, suggesting a more widespread
network of modifications leading to cell-cycle dysregulation.
Further highlighting the complex role of TET2 in regulating cell
proliferation, this process could not be influenced by modu-
lating 5hmC deposition in Tet2/ cells, and could only be
rescued by re-expression of TET2 itself, regardless of its cata-
lytic activity.
Although the exact mechanism by which TET2 regulates cell
proliferation remains to be understood, it is likely to involve inter-
actions with other co-regulators. For example, incorporation of
TET1 into the SIN3A corepressor complex resulted in transcrip-
tional effects independent of the conversionof 5mC to 5hmC (Wil-
liams et al., 2011). While TET1 is expressed in mast cells at very
low levels, a related mechanism may be at play for TET2-medi-
ated regulation of cell proliferation. Indeed, TET2 is able to recruit
HDAC2during resolution of inflammation inmyeloid cells, leading
to the repression of Il6 gene transcription via histone deacetyla-
tion, that is, independently of hydroxymethylation (Zhang et al.,
2015). Although we tested a small subset of genes, we observed
only a very limited ability of the catalytic inactive TET2 to rescue
geneexpression; thiswas in agreementwith the fact that changes
in gene expression in Tet2-deleted cells appeared to be predom-
inantly 5hmC dependent. What is the exact proportion of genes
depending on TET2 catalytic activity, TET2 protein itself, or both
remains to be investigated. Previous reports investigating TET-in-
teracting complexes mapped the main region mediating protein-
protein interactions to the carboxy-terminal catalytic domain of
TET2 (Chen et al., 2013; Zhang et al., 2015); consistently, we
found that this same region was able to rescue proliferation of
Tet2-deleted mast cells, independently of its catalytic activity.
TET2 also was shown to interact with OGT and to promote its
enzymatic activity (Chen et al., 2013; Deplus et al., 2013).
Although we could not observe any strong change in overall pro-
tein O-GlcNAcylation in Tet2-deleted mast cells (Figure S6D),
more subtle differences cannot be ruled out.
To fully comprehend the complexity of epigenetic modifica-
tions, which for the most part cannot be easily recapitulated byCell Reports 15, 1566–1579, May 17, 2016 1575
dysregulated activity of one or a few TFs, it is also important to
recognize that DNA methylation dynamics can lead not only to
altered expression of TFs but also to altered affinity and speci-
ficity of TF binding. Indeed, a recent work identified protein
readers for 5mC and its oxidized derivatives by utilizing quantita-
tive mass-spectrometry-based proteomics (Spruijt et al., 2013),
revealing that each cytosine modification was able to recruit
distinct and dynamic sets of proteins, which were only partially
overlapping. More specifically for C/EBP TFs, CpG methylation
of cAMP response element (CRE) sequences also was shown
to enhance binding of C/EBPa compared to the unmethylated
form (Rishi et al., 2010). Taken together, changes in DNAmethyl-
ation can determine both direct alterations in gene transcription
and also altered binding of TFs and co-regulators, potentially re-
sulting in complex phenotypes that cannot be easily associated
with only one or a few genomic loci. In summary, we found that
TET2 regulates various aspects of mast cell biology, most
notably cell differentiation and proliferation. While mast cell dif-
ferentiation could be compensated for by modulating the activity
of other TET proteins, mast cell proliferation was strictly depen-
dent on TET2, with no compensatory effects by other TET family
members, further indicating that TET2 exerts functions that can
be independent from its enzymatic activity.
EXPERIMENTAL PROCEDURES
Mice and Cell Cultures
Mast cells were differentiated from the bone marrow of Tet2/mice (Ko et al.,
2011) and their Tet2+/+ and Tet2+/– littermates in the presence of IL-3 as
described (Deho’ et al., 2014; Mayoral and Monticelli, 2010). Mice were
8–12 weeks of age and both male and female, although for the majority of
the experiments male cells were used. All animal studies were performed in
accordance with the Swiss Federal Veterinary Office guidelines and were
approved by the Dipartimento della Sanita’ e della Socialita’. When needed,
in order to enrich Tet2/ mast cells to levels comparable to the Tet2+/+ cul-
tures, cells were stained for the surface markers Kit and/or FcεRIa and sepa-
rated by either sorting or positive selection using anti-PE-MicroBeads (Miltenyi
Biotec). Alternatively, cells were negatively selected by depleting the Gr1+
Mac1+ populations. All of these methods resulted in an enrichment of purified
mast cells up to at least 89%. VitC was added to cells already differentiated for
2.5 weeks and used at 10–50 mg/ml for 8–10 days. The NSC-34 murine motor
neuron-like cell line (Cashman et al., 1992) was maintained in DMEM, supple-
mentedwith 5%heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin, and 2mM L-glutamine. HEK293T cells were main-
tained in DMEM supplemented with 10% FBS, L-glutamine, penicillin, strepto-
mycin, 0.1 mM nonessential amino acids, and 50 mM b-mercaptoethanol.
Surface and Intracellular Cytokine Staining
The following antibodies were used for surface staining (all from BioLegend):
CD117 (Kit)-APC/Cy7 (or APC); FcεRIa-PE; Ly6G (Gr1)-PE/Cy7 (or fluorescein
isothiocyanate [FITC]); and CD11b (Mac1)-Pacific blue. Intracellular cytokine
staining was performed exactly as described (Deho’ et al., 2014; Rusca
et al., 2012). Briefly, cells were stimulated with 1 mg/ml IgE-anti-DNP and
0.2 mg/ml HSA-DNP (both from Sigma) for 3 hr, with the addition of 10 mg/ml
brefeldin A in the last 2 hr of stimulation. Cells were fixed with 4% paraformal-
dehyde prior to permeabilization and staining with the following antibodies:
IL-6-PE, TNF-a-PE/Cy7 (BioLegend), and IL-13-PE (eBioscience).
qRT-PCR
Total RNA was extracted using TRI reagent (MRC) and was retrotranscribed
using the qScript cDNA SuperMix kit (Quanta Biosciences). Primer sequences
for SYBR Green qRT-PCR and TaqMan primers and probes (Applied Bio-
systems) are listed in Table S1. The qPCR was performed with an ABI1576 Cell Reports 15, 1566–1579, May 17, 20167900HT Fast Real-Time PCR system (Applied Biosystems). Data analysis
was performed using the DDCt method (Livak and Schmittgen, 2001).
Plasmid Construction
Lentiviral vectors were generated using standard cloning techniques. The mu-
rine Cebpa lentiviral expression vector was purchased from ABM (pLentiGIII-
EF1a; NCBI: NM_007678) and either used as is or moved into the pScalps
lentiviral vector (Deho’ et al., 2014). The murine Cebpe gene (NCBI:
NM_207131) was cloned by PCR from murine LSK (Lin– Sca1+ Kit+) hemato-
poietic progenitors isolated from the bone marrow. The sequences of shRNAs
against murine Tet3 were as follows: sh1, 50-CTGTTAGGCAGATTGTTCT; and
sh2, 50-TCCAACGAGAAGCTATTTT. The myc-tagged TET2 carboxy-terminal
catalytic DSBH domain with or without substitutions to impair its catalytic
activity (TET2 H 3 D) (Ko et al., 2010) was cloned into the pScalps lentiviral
vector. All inserts and mutations were verified by Sanger sequencing.
Lentiviral Transduction
Lentiviral transductions were performed exactly as described (Deho’ et al.,
2014; Mayoral and Monticelli, 2010). Briefly, viral particles were generated
by co-transfection of HEK293T cells with the lentiviral vector together with
packaging vectors psPAX2 and pMD2.G (Addgene 12260 and 12259). After
concentration by centrifugation, viral particles were added to the cell cultures.
Total bone marrow cells were used for most transductions, although in some
experiments Lin– hematopoietic precursors were first isolated from the bone
marrow using a Lineage Cell Depletion Kit (Miltenyi Biotec). Cells were
selected 2–3 days after transduction with 1–2 mg/ml puromycin for 24–48 hr.
Cell Proliferation
Cell proliferation in response to IL-3 was assessed by BrdU incorporation
assay exactly as described (Deho’ et al., 2014), utilizing an APC-BrdU Flow
kit from BD Biosciences. Cells were allowed to incorporate BrdU for 8–12 hr
at 37C.
RNA-Seq
Total RNA (1 mg) was used for mRNA-seq library preparation using the TruSeq
RNA Sample Prep kit (Illumina), according to the manufacturer’s instructions.
Sequencing was performed on a Solexa HiSeq2000 with standard protocols.
After quality filtering according to the Illumina pipeline, 51-bp paired-end reads
were aligned to the mm9 reference genome, NCBI Build 37, and to the Mus
musculus transcriptome (University of California, Santa Cruz [UCSC] and
Illumina’s iGenomes) using TopHat version 1.3.1 (Trapnell et al., 2012).
Sequencing statistics for each sample are reported in Table S2. DEGs were
identified with Cuffdiff v.2.0.2 (Trapnell et al., 2013) using two biological repli-
cates with the following parameters: minimal FPKM in at least one condition
(WT or knockout) R1; 2-fold in gene expression (WT versus knockout); and
p value% 0.05. The complete lists of up- and downregulated genes are pro-
vided in Table S3. Identification of enriched GO functional categories in the
set of genes up- or downregulated in Tet2/ mast cells was performed with
GoTermFinder (p value % 0.01) (Boyle et al., 2004) and REVIGO (Supek
et al., 2011). The complete lists of functional categories are provided in Tables
S4 and S5. Statistical enrichment of TF consensus DNA-binding sites was
scored using PSCAN (Zambelli et al., 2009) and a manually curated library of
PWMs as described (Barozzi et al., 2014). The complete lists of over-repre-
sented TF subfamilies are provided in Tables S6 and S7.
5hmC Quantification by Dot Blot
Levels of 5hmC were measured exactly as described (Ko et al., 2010; Leoni
et al., 2015). Briefly, DNA was isolated with the EZNA Tissue DNA kit (Omega
Biotek) and denatured. The 2-fold dilutions, from a starting amount of
100–500 ng, were spotted on a nitrocellulose membrane prior to incubation
with an anti-5hmC antibody (Active Motif).
Enrichment-Based Detection of 5hmC
Two independent biological replicates were sequenced by GLIB-seq. Chemi-
cal labeling-based 5hmC enrichment was performed utilizing the Hydroxy-
methyl Collector-seq kit (ActiveMotif) (Song et al., 2011). Briefly, 4 mg genomic
DNA was fragmented to 200–400 bp with a Covaris S2 sonicator (250-bp
protocol for 150 s), purified with 13 AMPure XP beads (Agencourt), and then
subjected to biotin-based enrichment of 5hmC. The 5hmC-enriched frag-
ments were processed for Illumina sequencing as described (Garber et al.,
2012) with slight modifications (Ostuni et al., 2013).
GLIB-Seq Data Processing and Peak Calling
For each dataset, low-quality reads were filtered out according to the Illumina
pipeline, and the remaining reads were mapped to the mouse reference
genome mm9 using Bowtie2 (Langmead and Salzberg, 2012), with ‘‘very sen-
sitive’’ preset of parameters. Reads showing multiple mapping and unknown
physical andmitochondrial DNAmapping were excluded from further analysis.
Duplicate reads were marked and removed using SAMtools (Li et al., 2009).
Peaks with significantly enriched signal were called using MACS2 (version
2.1.0.20150731, https://github.com/taoliu/MACS/), with the following added
parameters: -g mm -B–SPMR–nomodel–extsize 200 -p 1.00e04 (Zhang
et al., 2008). The direct comparisons Tet2+/+ versus Tet2/ and Tet2/
versus Tet2+/+ were performed with the same parameters. Peaks enriched in
Tet2+/+ versus Tet2/were defined as hypo while regions enriched in Tet2/
versus Tet2+/+ were defined as hyper. Peaks were filtered based on peaks
blacklisted by the Encyclopedia of DNA Elements (ENCODE) consortium anal-
ysis of artifactual signals in mouse cells (https://sites.google.com/site/
anshulkundaje/projects/blacklists). Genome browser tracks were normalized
such that each value represents the read per million (RPM) and converted to
the bigWig format for visualization on the UCSC Genome Browser using
bedGraphToBigWig tool.
Scatterplot of GLIB-Seq Regions
For visualization purposes, all regions identified above were pooled and their
coordinates merged in case of overlap. CoverageBed (Quinlan and Hall,
2010) was then used to compute coverage, which was transformed to reads
per kilobase per million mapped reads (RPKM) and log2-transformed for
each region. R software was used to generate the scatterplot.
Determination of Genomic Localization
The genomic localization of peaks was carried out using annotatePeaks (Heinz
et al., 2010) based onmm9 RefSeq as reference. We classified peaks as either
proximal or distal based on their proximity to TSSs. Proximal peaks were
located within ±2.5 kb from the TSS while all other peaks were classified as
distal.
Functional Enrichment Analysis
For each list of enriched regions of interest, GREAT 3.0.0 (McLean et al., 2010)
was used with default parameters and selecting the whole mm9 genome
as background. The complete lists of functional categories are provided in
Table S8.
H3K4me1 ChIP-Seq
ChIP-seq was performed as described (Ostuni et al., 2013). The
following MACS2 parameters were used: -g mm -B–SPMR–nomodel–extsize
146 -p 1.00e04.
Statistical Analysis
Statistical analysis was performed with Prism software (GraphPad). Data are
represented as mean ± SEM, and significance was assessed by paired or un-
paired Student’s t test, two-tailed, or two-way ANOVA.
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